CPT® Code 95857

1. Indications

The cholinesterase inhibitor challenge test is indicated for the evaluation of myasthenia gravis, particularly in patients presenting with symptoms that may suggest this condition. The following indications are explicitly recognized for performing this test:

• Facial Muscle Weakness Patients may exhibit weakness in facial muscles, which can affect expressions and overall facial appearance.
• Ptosis The drooping of one or both eyelids is a common symptom associated with myasthenia gravis.
• Double or Blurred Vision Visual disturbances, including diplopia (double vision), can occur due to muscle weakness affecting the ocular muscles.
• Difficulty Swallowing Patients may experience dysphagia, which is the medical term for difficulty in swallowing, due to weakness in the muscles involved in this process.
• Speech Disturbances Changes in speech patterns, such as slurred speech, may arise from weakness in the muscles responsible for articulation.

2. Procedure

The cholinesterase inhibitor challenge test involves several critical procedural steps to ensure accurate diagnosis and assessment of myasthenia gravis. The following steps outline the procedure:

• Step 1: Patient Preparation Prior to the test, the patient is prepared by obtaining a thorough medical history and conducting a physical examination to assess symptoms related to myasthenia gravis. Informed consent is obtained from the patient, explaining the procedure and its purpose.
• Step 2: Administration of Cholinesterase Inhibitor The test begins with the intravenous administration of a cholinesterase inhibitor, typically edrophonium. This medication works by inhibiting the enzyme that breaks down acetylcholine, thereby increasing its availability at the neuromuscular junction.
• Step 3: Evaluation of Muscle Strength After the administration of the cholinesterase inhibitor, the patient is closely monitored for any changes in muscle strength. The clinician evaluates the patient's ability to perform specific movements or tasks that assess muscle function.
• Step 4: Dose Adjustment If there is no observable improvement in muscle strength following the initial dose, progressively higher doses of the cholinesterase inhibitor may be administered. This step is crucial to determine if a positive response can be elicited with increased medication.
• Step 5: Interpretation of Results The clinician interprets the results based on the patient's response to the cholinesterase inhibitor. An improvement in muscle strength indicates a negative result for myasthenia gravis, while a lack of improvement may suggest the presence of the condition.

3. Post-Procedure

Following the cholinesterase inhibitor challenge test, the patient is monitored for any adverse reactions to the medication, as well as for the duration of the effects of the cholinesterase inhibitor. It is essential to observe the patient for signs of muscle weakness or respiratory distress, which may require immediate medical attention. The clinician will provide instructions regarding any necessary follow-up appointments and discuss the implications of the test results. If the test indicates a diagnosis of myasthenia gravis, further treatment options and management strategies will be discussed with the patient to address their specific needs.